Medicus Pharma to Highlight Rationale for CD228V Co-Development and License Agreement

Capital efficiency strategy prioritizes CD228V development while seeking separate public listing for SkinJect® and partners to advance Teverelix® PHILADELPHIA, PA / ACCESS Newswire / November 9, 2026 / Medicus Pharma Ltd. (NASDAQ:MDCX) …